MarginsXMarginsX
Home › Markets › Health Care › HURA

TuHURA Biosciences Inc. (HURA)

HURA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.33
-4.32% on the day
Market cap
$87.5M
Micro cap
Revenue · 2025
$0
Prior year not contiguous
Net income · 2025
-$30.1M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1498382/000119312526134950/0001193125-26-134950-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerHURA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001498382
SEC industry codePharmaceutical Preparations
Incorporated inNV

Financials · 2025

LineValue
Revenue$0
Net income-$30.1M
Operating incomeNot in SEC XBRL data
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$3.6M
Total assets$27.4M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
0.4 months
$996K cash at June 30, 2026
Share count, 1 year
+28.3%
2025-11-11 to 2026-11-10 · -32.1% over 3 years
Going-concern doubt
No
10-Q filed November 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-13
Cash and burn$996K cash; operating cash flow -$7.4M a quarter.Report 2026-06-30
Shares outstanding65,758,417 (2026-11-10); 51,258,085 a year earlier; 3,387,808,000 three years earlier. 3y figure adjusted for splits (1-for-35 overall).Cover page 2026-11-10
Reverse splits, 3 years1; latest 1-for-35 on 2024-10-18Source 2024-10-18
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-04-08
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-01-30
AuditorCherry Bekaert LLP, Tampa, Florida, United States; changed auditors 1 time in 24 months8-K 4.01 2025-01-03
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q4 2026
2026-06-30
Not filed-$9.2M-$8.6M$996K$3.6MNeeds four quarters10-Q 2026-08-14
Q3 2026
2026-03-31
$0-$7.5M-$4.4M$6.3MNo debt tags$010-Q 2026-05-15
Q2 2026
2025-12-31
$0-$6.8M-$5.6M$3.6MNo debt tags$010-K 2026-03-31
Q1 2026
2025-09-30
$0-$7.1M-$11.1M$2.7M$493K$010-Q 2025-11-14
Q4 2025
2025-06-30
$0-$9.5M-$6.2M$8.5M$434K$010-Q 2025-08-14
Q3 2025
2025-03-31
$0-$6.7M-$4.7M$6.2MNo debt tags$010-Q 2026-05-15
Q2 2025
2024-12-31
$0-$6.0M-$2.6M$12.7MNo debt tags$010-K 2026-03-31
Q1 2025
2024-09-30
$0-$5.6M-$1.9M$3.0MNo debt tagsNeeds four quarters10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-04-08
Latest annual report10-K/A2026-04-30
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-13
Latest proxyDEFA14A2026-07-09

Source: SEC EDGAR submissions feed, 931 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-14.7%
1 month-23.2%
3 months-39.6%
Year to date+83.6%
1 year-31.9%
From 52-week high-55.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
KZIAKazia Therapeutics Limited$5.60-15.41%$87.1M
GNLXGenelux Corporation$1.92+2.95%$86.9M
NKTXNkarta Inc.$1.21+1.68%$86.8M
RLYBRallybio Corporation$15.43-1.88%$86.4M
ANIXAnixa Biosciences Inc.$2.55-2.67%$88.6M
PMVPPMV Pharmaceuticals Inc.$1.19-6.30%$89.9M
RTSNRetension Pharmaceuticals Inc.$11.46-6.60%$90.3M
NBPNovaBridge Biosciences$0.7915-6.87%$91.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier